Journal of the European Academy of Dermatology and Venereology

Papers
(The H4-Index of Journal of the European Academy of Dermatology and Venereology is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Announcement363
Editor's Picks January 2024234
Announcement232
121
Pioneers in Dermatology and Venereology: An Interview with Professor An Goossens112
Announcement111
2013–2023: A decade of progress and challenges in dermatology as reflected in JEADV110
Paradoxical joint and muscle pain in a patient treated with anifrolumab and belimumab106
Reply to comments by Tadulewicz and Muklewicz on socio‐economic outcomes of atopic dermatitis102
Louis Adolphus Duhring: An enduring legacy97
Comparison of molecular and serological assays on cerebrospinal fluid for the diagnosis of neurosyphilis85
Advances in biologic therapy of psoriasis84
Comparison of performance of SCORTEN, ABCD‐10 and Re‐SCORTEN in a cohort of patients with Stevens–Johnson syndrome/toxic epidermal necrolysis80
Course and outcome of chilblain‐like acral lesions during COVID‐19 pandemic73
High prevalence of extracutaneous involvement in ITG junctional epidermolysis bullosa72
Risk analysis of systemic side effects of tumescent local anaesthesia in the surgical treatment of geriatric and multimorbid patients with skin cancer71
Disproportionate quality of life decline and unaddressed limitations in amlitelimab atopic dermatitis trial71
Are non‐fungible tokens the barrier to realizing the Dermoverse?71
Genetic susceptibility in early‐onset melanoma: An observational Greek cohort study68
Global burden of major depressive disorder attributable to psoriasis, 2000–202167
Intriguing concept of pigmented contact dermatitis: Further understanding the role of hair colours including natural henna63
Aquagenic pruritus: A web‐based survey study exploring itch characteristics, therapeutic options and patient perspectives61
Hand–foot syndrome like eruption following mRNA COVID‐19 vaccine60
Comment on ‘Negative SARS‐CoV‐2 antibodies in patients with positive immunohistochemistry for spike protein in pityriasis rosea‐like eruptions’58
Impact of menopause on the skin…information still insufficient57
Issue Information57
57
Contact allergy may enhance further sensitization to new chemicals, but individual susceptibility traits are important for polysensitization56
56
Announcement56
Announcement55
The affliction of job, as painted by Jusepe de Ribera: A dermatological observation going back to the 17th century54
Juvenile localized scleroderma: A single‐centre experience from India53
Comment on ‘Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity’ by Dupuis et al.53
Dalbavancin for the treatment of severe hidradenitis suppurativa52
The chicken or the egg of lymphopenia in atopic eczema50
A case of eruptive halo nevi following COVID‐1950
Pharmacovigilance: The responsibility of all49
The future of digital pills and their potential use in dermatological clinical trials49
Erythema multiforme major associated with molnupiravir treatment for SARS‐CoV‐2 infection: First report49
Educational, labour market and relationship outcomes in people with acne48
Rituximab in immunobullous disorders during the COVID‐19 pandemic: A systematic review of observational studies48
Automated dermatoscopic pattern discovery by clustering neural network output for human–computer interaction48
Editor’s Picks June 202548
Barrier function‐related genes and proteins have an altered expression in acne‐involved skin47
Multiple basal cell carcinomas revealing a biallelic MUTYH gene mutation in a 39‐year‐old male patient45
0.14316487312317